Skip to main content
. 2016 Jul 18;7(33):53628–53641. doi: 10.18632/oncotarget.10682

Table 1. Expression of glutamine metabolism-related proteins according to the histologic subtype of thyroid cancer.

Parameters Total
N= 557(%)
PTC
n= 344(%)
FC
n= 112(%)
MC
n= 70(%)
PDC
n= 23(%)
AC
n= 8(%)
p-value
GLS1 (T) <0.001
 Negative 247 (44.3) 141 (41.0) 70 (62.5) 27 (38.6) 9 (39.1) 0 (0.0)
 Positive 310 (55.7) 203 (59.0) 42 (37.5) 43 (61.4) 14 (60.9) 8 (100.0)
GLS1 (S) <0.001
 Negative 554 (99.5) 344 (100.0) 112 (100.0) 70 (100.0) 23 (100.0) 5 (62.5)
 Positive 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (37.5)
GDH (T) <0.001
 Negative 105 (18.9) 43 (12.5) 48 (42.9) 11 (15.7) 3 (13.0) 0 (0.0)
 Positive 452 (81.1) 301 (87.5) 64 (57.1) 59 (84.3) 20 (87.0) 8 (100.0)
GDH (S) <0.001
 Negative 549 (98.6) 341 (99.1) 112 (100.0) 70 (100.0) 22 (95.7) 4 (50.0)
 Positive 8 (1.4) 3 (0.9) 0 (0.0) 0 (0.0) 1 (4.3) 4 (50.0)
ASCT2 (T) <0.001
 Negative 459 (82.4) 289 (84.0) 103 (92.0) 43 (61.4) 17 (73.9) 7 (87.5)
 Positive 98 (17.6) 55 (16.0) 9 (8.0) 27 (38.6) 6 (26.1) 1 (12.5)

PTC; papillary thyroid carcinoma, FC; follicular carcinoma, MC; medullary carcinoma, PDC; poorly differentiated carcinoma, AC; anaplastic carcinoma, GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2